2. Anti-infection Metabolic Enzyme/Protease Stem Cell/Wnt MAPK/ERK Pathway Neuronal Signaling
  3. Reverse Transcriptase Endogenous Metabolite ERK Amyloid-β
  4. Pyridoxal phosphate

Pyridoxal phosphate  (Synonyms: Pyridoxal 5′-phosphate; Pyridoxyl phosphate)

Cat. No.: HY-B1744 Purity: 99.85%
SDS
COA
Handling Instructions Technical Support

Pyridoxal phosphate is the active form of vitamin B6, acts as an inhibitor of reverse transcriptases, and is used for the treatment of tardive dyskinesia.

For research use only. We do not sell to patients.

Pyridoxal phosphate Chemical Structure

Pyridoxal phosphate Chemical Structure

CAS No. : 54-47-7

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
100 mg In-stock
1 g In-stock
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Pyridoxal phosphate:

Pyridoxal phosphate Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Pyridoxal phosphate

View All ERK Isoform Specific Products:

View All Isoforms
ERK ERK1 ERK2 ERK5 ERK8

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Pyridoxal phosphate is the active form of vitamin B6, acts as an inhibitor of reverse transcriptases, and is used for the treatment of tardive dyskinesia.

IC50 & Target

Human Endogenous Metabolite

 

In Vitro

Pyridoxal 5′-phosphate severely inhibits the DNA Polymerase and RNase H. Pyridoxal phosphate results in an imnediate reduction in the rate of DNA synthesis[1]. Conjugation to pyridoxal phosphate fully inhibits NEIL2. Pyridoxal phosphate-conjugated NEIL2 shows much lower activity than the intact enzyme over a wide range of enzyme/substrate ratios. After Pyridoxal phosphate conjugation, the ability of NEIL2 to bind the THF-ligand is completely lost[2]. Pyridoxal phosphate (500 μM, 24 h) activates the ERK/c-Jun signaling pathway, promotes the expression of IGFBP1 protein in HepG2 cells[3].
Pyridoxal phosphate (0.5 mg/mL, 48h) inhibits the proliferation of cancer cells SK-OV-3 and OVCAR-3[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pyridoxal phosphate Related Antibodies

Western Blot Analysis[3]

Cell Line: HepG2
Concentration: 500 μM
Incubation Time: 24 h
Result: Promoted the phosphorylation of ERK1 and c-Jun protein.

Cell Proliferation Assay[5]

Cell Line: SK-OV-3 and OVCAR-3
Concentration: 0.5 mg/mL
Incubation Time: 48 h
Result: Inhibited the proliferation.
In Vivo

Pyridoxal phosphate (1 mg/kg, ip, single dose) alleviates Aβ25-35-induced spatial memory impairment and long-term memory impairment in mouse models[4].
Pyridoxal phosphate (600 mg/kg/day, po for 16 weeks) inhibits the formation of advanced glycation end-products (AGEs), and prevents the progression of diabetic nephropathy in Streptozotocin (HY-13753)-induced rats diabetes model[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Aβ25-35-induced cognitive dysfunction in ICR mouse models[4]
Dosage: 1 mg/kg
Administration: ip, single dose
Result: Alleviated spatial and long-term memory impairment.
Animal Model: Streptozotocin (HY-13753)-induced rats diabetes model[6]
Dosage: 600 mg/kg
Administration: po for 16 weeks
Result: Prevented the diabetes.
Clinical Trial
Molecular Weight

247.14

Formula

C8H10NO6P
CAS No.
Appearance

Solid

Color

Off-white to yellow

SMILES

O=CC1=C(O)C(C)=NC=C1COP(O)(O)=O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 62.5 mg/mL (252.89 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : 5 mg/mL (20.23 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.0463 mL 20.2314 mL 40.4629 mL
5 mM 0.8093 mL 4.0463 mL 8.0926 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (10.12 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (10.12 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 2 mg/mL (8.09 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.85%

SDS (393 KB)

COA (251 KB) HNMR (251 KB) RP-HPLC (253 KB) MS (75 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 4.0463 mL 20.2314 mL 40.4629 mL 101.1572 mL
5 mM 0.8093 mL 4.0463 mL 8.0926 mL 20.2314 mL
10 mM 0.4046 mL 2.0231 mL 4.0463 mL 10.1157 mL
15 mM 0.2698 mL 1.3488 mL 2.6975 mL 6.7438 mL
20 mM 0.2023 mL 1.0116 mL 2.0231 mL 5.0579 mL
DMSO 25 mM 0.1619 mL 0.8093 mL 1.6185 mL 4.0463 mL
30 mM 0.1349 mL 0.6744 mL 1.3488 mL 3.3719 mL
40 mM 0.1012 mL 0.5058 mL 1.0116 mL 2.5289 mL
50 mM 0.0809 mL 0.4046 mL 0.8093 mL 2.0231 mL
60 mM 0.0674 mL 0.3372 mL 0.6744 mL 1.6860 mL
80 mM 0.0506 mL 0.2529 mL 0.5058 mL 1.2645 mL
100 mM 0.0405 mL 0.2023 mL 0.4046 mL 1.0116 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Pyridoxal phosphate Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Pyridoxal54-47-7Pyridoxal 5′-phosphatePyridoxylReverse TranscriptaseEndogenous MetaboliteERKAmyloid-βExtracellular signal regulated kinasesβ-amyloid peptideAβAbetaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Pyridoxal phosphate
Cat. No.:
HY-B1744
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.